植入式心脏转换器-除器的经济结果
1Medtronic Inc, Minneapolis, Minn, and Charles River Associates Inc, Boston, MA, USA. marshall.stanton@medtronic.com
Circulation
|March 7, 2000
概括
植入式心脏转换器-除器 (ICD) 治疗对于管理心室心律失常是具有成本效益的. 根据目前的技术,ICD治疗成本可能会在1至3年内实现收支平衡,预计未来会有改善.
科学领域:
- 心脏病学 心脏病学
- 卫生经济学 卫生经济学
背景情况:
- 关于植入式心脏转换器-除器 (ICD) 治疗的成本效益的文献综述.
- 对心室动和心跳动管理的经济结果研究的分析.
研究的目的:
- 评估ICD治疗与抗失常药物相比的成本效益.
- 评估技术和实践模式对ICD成本效益的影响.
主要方法:
- 选了1990-1997年的文献,用于成本效益分析.
- 包括随机试验,前性/后性研究和经济模型.
- 分析了增量成本效益比率 (ICER).
主要成果:
- 对于ICD治疗的ICER范围从成本节省到每生命年节省的114,917美元 (LYS).
- 归因于研究设计,方法,技术和后续持续时间的变化.
- 在目前的做法下,ICD治疗成本可能会在1-3年内破解.
结论:
- 最近的文献支持ICDs作为对危及生命的腹腔动脉节律失常的成本效益.
- 预计新技术和管理实践将提高成本效益.
- 未来的研究应该考虑后续持续时间和生活质量的影响.
相关概念视频
Dysrhythmias VI: Management of Dysrhythmias
598
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
598
Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
Cardiomyopathy II: Dilated Cardiomyopathy
798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
Cardiomyopathy V: Interprofessional Care
761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761


